NCIt definition : A human bispecific immunoglobulin G1 (IgG1) antibody targeting the tumor-associated
antigens (TAAs) epidermal growth factor receptor (EGFR) and hepatocyte growth factor
receptor (HGFR; c-Met), with potential antineoplastic activity. Upon administration,
pamvatamig simultaneously targets and binds to the extracellular domains of both EGFR
and c-Met expressed on cancer cells. This prevents the activation of both EGFR- and
c-Met-mediated signaling pathways. The binding results in antibody-dependent cellular
cytotoxicity (ADCC), thereby inhibiting tumor cell proliferation and survival. EGFR
and c-Met, both upregulated or mutated in a variety of tumor cell types, play key
roles in tumor cell proliferation.;
UNII : X3U67W8G5W;
CAS number : 2750004-05-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2750004-05-6
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)